Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

6.015 +0.015 (+0.25%)

Streaming Delayed Price Updated: 12:57 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' ↗

May 09, 2024

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

Via Benzinga

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

May 08, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

April 25, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts ↗

March 11, 2024

Via Benzinga

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023 ↗

March 07, 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Recap: Arcturus Therapeutics Q4 Earnings ↗

March 07, 2024

Via Benzinga

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

March 07, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Evaluating NASDAQ:ARCT for Growth Investment Opportunities. ↗

February 27, 2024

High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this.

Via Chartmill

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

Is NASDAQ:ARCT suited for growth investing? ↗

February 06, 2024

Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing?

Via Chartmill

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

Earnings Preview: Arcturus Therapeutics ↗

March 06, 2024

Via Benzinga

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

February 26, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

February 22, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 ↗

February 21, 2024

Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.

Via InvestorPlace

3 Tech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 20, 2024

We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today.

Via InvestorPlace

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

February 20, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

February 05, 2024

From Arcturus Therapeutics

Via Business Wire

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 23, 2024

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.

Via Benzinga

Topics Stocks

Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT). ↗

January 16, 2024

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations ↗

December 26, 2023

Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).

Via Chartmill

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

December 21, 2023

From Arcturus Therapeutics

Via Business Wire

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗

December 17, 2023

While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.

Via InvestorPlace

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 ↗

December 13, 2023

These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.

Via InvestorPlace

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside ↗

December 13, 2023

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 04, 2023

Via Benzinga

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 04, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Why the growth investor may take a look at NASDAQ:ARCT. ↗

December 04, 2023

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

November 28, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.